Resistant Hypertension Management: Comparison of the 2017 American and 2018 European High Blood Pressure Guidelines
- 204 Downloads
Purpose of Review
To compare European and American guidelines for the diagnosis, evaluation, and management of resistant hypertension.
Resistant hypertension is defined as high blood pressure that remains above goal with the use of 3 or more antihypertensive agents, commonly a renin-angiotensin blocker (either an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker), a long-acting calcium channel blocker, and thiazide or thiazide-like diuretic. Resistant hypertension is common, with a recent analysis indicating that it affects approximately 17–19% of adult Americans with hypertension. Pseudocauses of apparent resistant hypertension, including inaccurate blood pressure measurement, white coat effect, undertreatment, and poor medication adherence, must be excluded in order to confirm true resistant hypertension. Evaluation of resistant hypertension requires identifying and treating secondary causes of hypertension, including obstructive sleep apnea, primary aldosteronism, and renal artery stenosis. Treatment of resistant hypertension includes a combined use of lifestyle modification and prescription of effective multiple-drug combinations. Preferential use of a long-acting thiazide-like diuretic, either chlorthalidone or indapamide, and a mineralocorticoid receptor blocker, most commonly spironolactone, is recommended if needed to achieve blood pressure control.
Aside for small exceptions, European and American guidelines agree in terms of recommendations for diagnosing, evaluating, and treating resistant hypertension.
KeywordsResistant hypertension Pseudoresistance White coat effect Adherence Aldosteronism Spironolactone
David Calhoun’s research was supported by the National Institutes of Health (R01 HL113004) and the American Heart Association Strategically Focused Research Network (AHA 5SFRN2390002). Robert M. Carey’s research is supported by the National Institutes of Health (R01 HL 128189 and P01 HL 074940).
Compliance with Ethical Standards
Conflict of Interest
The authors declare no conflicts of interest relevant to this manuscript.
Human and Animal Rights and Informed Consent
All reported studies/experiments with human subjects or animals performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional/national research committee standards, and international/national/institutional guidelines).
Papers of particular interest, published recently, have been highlighted as: •• Of major importance
- 2.Collaborators GBDRF. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1345–422.Google Scholar
- 5.Fryar DC, Ostchega Y, Hales CM, Zhang G, Kruszon-Moran D. Hypertension prevalence and control among adults: United States, 2015–2016. NCHS data brief, no 289 Hyattsville, MD: National Center for Heatlh Statistics. 2017.Google Scholar
- 6.•• Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6):e13–e115 The 2017 ACC/AHA clinical practice guideline for high blood pressure in adults provides and redefines resistant hypertension and provides a diagnostic and therapeutic algorighm for this disorder. PubMedGoogle Scholar
- 7.Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, et al. Heart disease and stroke statistics-2019 update: a report from the American Heart Association. Circulation. 2019;139(10):e56–e528.Google Scholar
- 8.Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365(9455):217–23.Google Scholar
- 9.•• Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021–104 The 2018 ESC/ESH clinical practice guideline on high blood pressure in adults provides specific recommendations for the management of resistant hypertension. PubMedGoogle Scholar
- 10.•• Carey RM, Calhoun DA, Bakris GL, Brook RD, Daugherty SL, Dennison-Himmelfarb CR, et al. Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association. Hypertension. 2018;72(5):e53–90 The 2018 AHA scientific statement on resistant hypertension is a dedicated analysis of the disorder and provides algorithms for evaluation and management.PubMedPubMedCentralGoogle Scholar
- 15.Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103–16.Google Scholar
- 17.Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High lood Pressure Research. Hypertension. 2008;51(6):1403–19.PubMedGoogle Scholar
- 20.Bhatt H, Siddiqui M, Judd E, Oparil S, Calhoun D. Prevalence of pseudoresistant hypertension due to inaccurate blood pressure measurement. J Am Soc Hyperten : JASH. 2016;10(6):493–9.Google Scholar
- 29.Rogers A, Necola O, Sexias A, Luka A, Newsome V, Williams S, et al. Resistant hypertension and sleep duration among blacks with metabolic syndrome MetSO. J Sleep Disord Treat Care 2016;5(4).Google Scholar
- 38.Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386(10008):2059–68.PubMedPubMedCentralGoogle Scholar
- 39.Williams B, MacDonald TM, Morant SV, Webb DJ, Sever P, McInnes GT, et al. Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies. Lancet Diab Endocrinol. 2018;6(6):464–75.Google Scholar